MedEdTalks Pulmonology is a continuing medical education podcast for physicians to allow them to learn while on the go and obtain CME credits. The intended audience for this show is pulmonologists, internists, rheumatologists and other health care professionals.
11 Episódios
Improving Adherence: Patient Engagement and Education With Drs. Elizabeth R. Volkmann and Kristin B. Highland
16:14
In this podcast, expert clinicians will discuss the strategies to improve patients adherence to therapy in SSc-ILD.Management of SSc-ILD: Guidelines and Treatment Options With Drs. Elizabeth R. Volkmann and Kevin R. Flaherty
17:49
In this podcast, expert clinicians will discuss evidence-based recommendations for the treatment of SSc-ILD.Não percas um episódio de “MedEdTalks - Pulmonology” e subscrevê-lo na aplicação GetPodcast.
Diagnosis of SSc-ILD: Screening and Monitoring of Lung Function With Drs. Elizabeth R. Volkmann and Kristin B. Highland
16:01
In this podcast, expert clinicians will discuss best practices in the diagnosis of SSc-ILD.Understanding SSc-ILD: Prevalence and Burden of Disease With Drs. Elizabeth R. Volkmann and Kevin R. Flaherty
14:36
In this podcast, expert clinicians will discuss the prevalence and burden of SSc-ILD.Treating a Patient With Refractory Nontuberculous Mycobacterial Lung Disease, with Drs. Anne O’Donnell and David Griffith
12:24
In this podcast, expert clinicians will discuss treatment for a patient with refractory Mycobacterium avium complex lung disease despite many months of guidelines-based therapy. For CME Credit, complete activity here: https://tinyurl.com/LungMET2Managing Mycobacterium Avium Complex Lung Infection in a Patient With Underlying Lung Disease, with Drs. Anne O’Donnell and Angela DiMango
14:27
In this podcast, expert clinicians will discuss treatment for Mycobacterium avium complex lung infection in a patient with underlying granulomatosis with polyangiitis affecting the lungs. For CME Credit, complete activity here: https://tinyurl.com/LungMET1Dr. Nathan and Dr. Patel Discuss a Challenging Case in Treating PF-ILD
15:03
Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss a challenging case on treating a patient with PF-ILD. Transcript: https://tinyurl.com/PF-ILD4Transcript For CME Credit, complete activity here: https://tinyurl.com/PF-ILD4Dr. Nathan and Dr. Patel Discuss a Challenging Case in Diagnosing PF-ILD
15:10
Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss a challenging case on diagnosing a patient with PF-ILD. Transcript: https://tinyurl.com/PF-ILD3Transcript For CME Credit, complete activity here: https://tinyurl.com/PF-ILD3Dr. Nathan and Dr. Lancaster Discuss a Challenging Case in Treating PF-ILD
16:32
Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss a challenging case on treating a patient with PF-ILD. Transcript: https://tinyurl.com/PF-ILD2Transcript For CME Credit, complete activity here: https://tinyurl.com/PF-ILD2Dr. Nathan and Dr. Lancaster Discuss a Challenging Case in Diagnosing PF-ILD
15:47
Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss a challenging case on diagnosing a patient with PF-ILD. Transcript: https://tinyurl.com/PF-ILD1Transcript For CME Credit, complete activity here: https://tinyurl.com/PF-ILD1
Descobre o mundo dos podcasts com a app gratuita GetPodcast.
Subscreve os teus podcasts preferidos, ouve episódios offline e obtém recomendações fantásticas.
© radio.de GmbH 2021